10X Fund, L.P. sold GALT

November 24, 2025 · Form 4 insider transaction

10X Fund, L.P. sold 24,000 shares of Galectin Therapeutics Inc., a transaction worth N/A. The trade was recorded as j and disclosed on an SEC Form 4, filed 24 days after the transaction.

Direction
Disposed (sell-side)
Shares
24,000
Price
N/A
Total value
N/A
Role—
SecurityCommon Stock
Transaction codeJ: J
Transaction dateNovember 24, 2025
Filing dateDecember 18, 2025
Shares owned after5,645,138
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.; 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

View the original Form 4 on SEC EDGAR